Adeno-associated virus (AAV)-6, 8, and 9 are promising gene-delivery vectors for testing novel Duchenne muscular dystrophy gene therapy in the canine model. Humoral immunity greatly influences in vivo AAV transduction. However, neutralizing antibodies to AAV-6, 8, and 9 have not been systemically examined in normal and dystrophic dogs. To gain information on the seroprevalence of antibodies to AAV-6, 8, and 9, we measured neutralizing antibody titers using an in vitro transduction inhibition assay. We examined 72 naive serum samples and 26 serum samples obtained from dogs that had received AAV gene transfer. Our data demonstrated that AAV-6 neutralizing antibody was the most prevalent antibody in dogs irrespective of age, gender, disease status (dystrophic or not), and prior parvovirus vaccination history. Surprisingly, high-level anti-AAV-6 antibody was detected at birth in newborn puppies. Further, a robust antibody response was induced in affected, but not normal newborn dogs following systemic AAV gene transfer. Taken together, our data have provided an important baseline on the seroprevalence of AAV-6, 8, and 9 neutralizing antibodies in normal and Duchenne muscular dystrophy dogs. These results will help guide translational AAV gene-therapy studies in dog models of muscular dystrophy.
BostickB., GhoshA., YueY.et al.2007. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther., 14:1605–1609.
BouchardG., Plata-MadridH., YoungquistR.S.et al.1992. Absorption of an alternate source of immunoglobulin in pups. Am. J. Vet. Res., 53:230–233.
5.
CalcedoR., VandenbergheL.H., GaoG.et al.2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis., 199:381–390.
6.
CooperB.J., WinandN.J., StedmanH.et al.1988. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature, 334:154–156.
7.
DayM.J.2007. Immune system development in the dog and cat. J. Comp. Pathol., 137,Suppl 1:S10–S15.
8.
DuanD.2011. Duchenne muscular dystrophy gene therapy: lost in translation?Res. Rep. Biol., 2:31–42.
9.
FelsburgP.J.1998. Immunology of the dog. In Handbook of Vertebrate Immunology. PastoretP.P., GriebelP., BazinH., GovaertsA.Academic Press: New York, NY, 261–288.
10.
FelsburgP.J.2002. Overview of immune system development in the dog: comparison with humans. Hum. Exp. Toxicol., 21:487–492.
11.
FineD.M., ShinJ.H., YueY.et al.2011. Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul. Disord, XX:XX–XX.
12.
GaoG., VandenbergheL.H., AlviraM.R.et al.2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol., 78:6381–6388.
13.
GaoG., VandenbergheL.H., WilsonJ.M.2005. New recombinant serotypes of AAV vectors. Curr. Gene Ther., 5:285–297.
14.
GaoG.P., AlviraM.R., WangL.et al.2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A., 99:11854–11859.
GregorevicP., AllenJ.M., MinamiE.et al.2006. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med., 12:787–789.
17.
GregorevicP., SchultzB.R., AllenJ.M.et al.2009. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol. Ther., 17:1427–1433.
18.
HalbertC.L., MillerA.D., McNamaraS.et al.2006. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum. Gene Ther., 17:440–447.
19.
HarperS.Q., HauserM.A., DellorussoC.et al.2002. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med., 8:253–261.
20.
HeddleR.J., RowleyD.1975. Dog immunoglobulins. I. Immunochemical characterization of dog serum, parotid saliva, colostrum, milk and small bowel fluid. Immunology, 29:185–195.
21.
HurlbutG.D., ZieglerR.J., NietupskiJ.B.et al.2010. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol. Ther., 18:1983–1994.
22.
KorhonenH., MarnilaP., GillH.S.2000. Milk immunoglobulins and complement factors. Br. J. Nutr., 84,Suppl 1:S75–S80.
23.
KornegayJ.N., TulerS.M., MillerD.M., LevesqueD.C.1988. Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve, 11:1056–1064.
24.
LaiY., ThomasG.D., YueY.et al.2009. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest., 119:624–635.
25.
MingozziF., HighK.A.2011. Immune responses to AAV in clinical trials. Curr. Gene Ther., 11:321–330.
26.
OhshimaS., ShinJ.H., YuasaK.et al.2009. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol. Ther., 17:73–80.
27.
PoffenbargerE.M., OlsonP.N., ChandlerM.L.et al.1991. Use of adult dog serum as a substitute for colostrum in the neonatal dog. Am. J. Vet. Res., 52:1221–1224.
28.
PollockR.V., CarmichaelL.E.1982. Maternally derived immunity to canine parvovirus infection: transfer, decline, and interference with vaccination. J. Am. Vet. Med. Assoc., 180:37–42.
29.
QiaoC., ZhangW., YuanZ.et al.2010. AAV6 capsid tyrosine to phenylalanine mutations improve gene transfer to skeletal muscle. Hum. Gene Ther., 21:1343–1348.
30.
RaptiK., Louis-JeuneV., KohlbrennerE.et al.2011. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol. Ther.In-press10.1038/mt.2011.177.
31.
ReynoldsH.Y., JohnsonJ.S.1970. Quantitation of canine immunoglobulins. J. Immunol., 105:698–703.
32.
RutledgeE.A., HalbertC.L., RussellD.W.1998. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol., 72:309–319.
33.
Schafer-SomiS., Bar-SchadlerS., AurichJ.E.2005. Immunoglobulins in nasal secretions of dog puppies from birth to six weeks of age. Res. Vet. Sci., 78:143–150.
34.
SharpN.J., KornegayJ.N., Van CampS.D.et al.1992. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics, 13:115–121.
35.
SheltonG.D., EngvallE.2005. Canine and feline models of human inherited muscle diseases. Neuromuscul. Disord., 15:127–138.
36.
ShinJ.H., YueY., SrivastavaA.et al.2011. A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum. Gene TherIn-press10.1089/hum.2011.147.
37.
SmithB.F., KornegayJ.N., DuanD.2007. Independent canine models of Duchenne muscular dystrophy due to intronic insertions of repetitive DNA. 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA, May June 30 3, 2007.
38.
SmithB.F., YueY., WoodsP.R.et al.2011. An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breed. Lab. Invest., 91:216–231.
39.
VandenbergheL.H., WilsonJ.M.2007. AAV as an immunogen. Curr. Gene Ther., 7:325–333.
40.
WangB., LiJ., XiaoX.2000. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U.S.A., 97:13714–13719.
41.
WangL., CalcedoR., WangH.et al.2010. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol. Ther., 18:126–134.
42.
WangZ., KuhrC.S., AllenJ.M.et al.2007. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther., 15:1160–1166.
43.
XiaoW., ChirmuleN., BertaS.C.et al.1999. Gene therapy vectors based on adeno-associated virus type 1. J. Virol., 73:3994–4003.
44.
YueY., LiZ., HarperS.Q.et al.2003. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation, 108:1626–1632.
45.
YueY., LiuM., DuanD.2006. C-terminal truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double knock-out mice. Mol. Ther., 14:79–87.
46.
YueY., GhoshA., LongC.et al.2008. A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol. Ther., 16:1944–1952.
47.
YueY., ShinJ.-H., DuanD.2011. Whole body skeletal muscle transduction in neonatal dogs with AAV-9. Methods Mol. Biol., 709:313–329.
48.
ZaissA.K., MuruveD.A.2008. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther., 15:808–816.
49.
ZhongL., LiB., MahC.S.et al.2008. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A., 105:7827–7832.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
